COMPOUND SCREENING AND SELECTION Clause Samples

The "Compound Screening and Selection" clause defines the process by which chemical compounds are evaluated and chosen for further research or development. Typically, this clause outlines the criteria and procedures for screening a library of compounds, such as through laboratory assays or computational analysis, and specifies how selected compounds are identified and communicated between parties. Its core function is to establish a clear, agreed-upon method for narrowing down a large pool of candidates to those with the most potential, thereby streamlining research efforts and reducing ambiguity in collaborative projects.
COMPOUND SCREENING AND SELECTION. 5.1 Screening to Identify Active Compounds.
View SourceView Similar (2)
COMPOUND SCREENING AND SELECTION. Cortex Compounds for Research ----------------------------- At the commencement of the Research, Cortex will make all Cortex Compounds available for screening pursuant to the Research Plan as selected by the Research Committee, along with the structures and properties (to the extent known) of such Cortex Compounds. Initially, all such Cortex Compounds shall be Restricted Compounds. Within [*] of the commencement of the Research, and provided that at the end of such [*] period [*] FTE's are available at Cortex to perform the Research, the Research Committee will release [*] Cortex Compounds to be Unrestricted Compounds, and will release an additional [*] Cortex Compounds each [*] days thereafter, until such time as not more than [*] Cortex Compounds, which are under active consideration, remain Restricted Compounds.
View Source
COMPOUND SCREENING AND SELECTION 
View Source

Related to COMPOUND SCREENING AND SELECTION

  • Background Screening and Security All Contractor employees, Subcontractors and agents of the Contractor performing work under the Contract must comply with all background screening and security requirements of the Department, as detailed below.

  • Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Screening The Health Plan must work with contracted providers to conduct interperiodic EPSDT screens on RIte Care and all ACA Adult Expansion Population members under age 21 (i.e. 19 and 20-year old under this Agreement) to identify health and developmental problems in conformance with ATTACHMENT ED to this Agreement. Additional screens should be provided as Medically Necessary. At a minimum, these screens must include: • A comprehensive health and developmental history, including health education, nutrition assessment, immunization history, and developmental assessment • Immunizations according to the Rhode Island EPSDT Periodicity Schedule • An unclothed physical examination • Laboratory tests including lead, TB, and newborn screenings as medically indicated • Vision testing • Hearing testing • Dental screening oral examination by PCP as part of a comprehensive examination required before age one (1) • All other medically indicated screening services • And provide EOHHS with a list of established CPT/HCPC codes used to identify all billable services included in the EPSDT schedule.